Deutsch English Français

Contact

EP1575606

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1575606

EP1575606 - TREATMENT OF OSTEOARTHRITIS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 17.01.2014 Database last updated on 19.10.2024
Most recent event Tooltip	17.01.2014	Application deemed to be withdrawn	published on 19.02.2014 [2014/08]
Applicant(s)	For all designated states Promics Pty Limited c/- Arana Therapeutics Limited Level 2 37 Epping Road Macquarie Park, NSW 2113 / AU
	[2009/04]
Former [2005/38]	For all designated states THE UNIVERSITY OF QUEENSLAND Brisbane Queensland 4072 / AU
Inventor(s)	01 / SHIELS, Ian Alexander 17 Sherlock Road Muirlea Road Muirlea, Queensland 4306 / AU
	02 / FAIRLIE, David 73 Trevallyan Drive Springwood, Queensland 4127 / AU
	[2005/38]
Representative(s)	Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
	[N/P]
Former [2008/35]	Vossius & Partner Siebertstrasse 3 81675 München / DE
Former [2005/38]	Vossius & Partner Siebertstrasse 4 81675 München / DE
Application number, filing date	03750172.3	16.10.2003
	[2005/38]
	WO2003AU01373
Priority number, date	AU20020952086	16.10.2002 Original published format: AU 2002952086
	[2005/38]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2004035079
	Date:	29.04.2004
	Language:	EN
	[2004/18]
	Type:	A1 Application with search report
	No.:	EP1575606
	Date:	21.09.2005
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 29.04.2004 takes the place of the publication of the European patent application.
	[2005/38]
Search report(s)	International search report - published on:	AU	29.04.2004
	(Supplementary) European search report - dispatched on:	EP	02.03.2010
Classification	IPC:	A61K38/08, A61K38/12, A61P19/02	[2005/38]
	CPC:	A61K38/12 (EP,US); A61P19/02 (EP); A61P43/00 (EP)
	C-Set:	A61K38/12, A61K2300/00 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/38]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
Title	German:	BEHANDLUNG VON OSTEOARTHRITIS	[2005/38]
	English:	TREATMENT OF OSTEOARTHRITIS	[2005/38]
	French:	TRAITEMENT DE L'ARTHROSE	[2005/38]
Entry into regional phase	13.05.2005	National basic fee paid
	13.05.2005	Search fee paid
	13.05.2005	Designation fee(s) paid
	13.05.2005	Examination fee paid
Examination procedure	14.05.2004	Request for preliminary examination filed International Preliminary Examining Authority: AU
	13.05.2005	Examination requested [2005/38]
	02.07.2010	Despatch of a communication from the examining division (Time limit: M06)
	26.04.2011	Reply to a communication from the examining division
	03.04.2012	Despatch of a communication from the examining division (Time limit: M04)
	26.07.2012	Reply to a communication from the examining division
	12.04.2013	Communication of intention to grant the patent
	23.08.2013	Application deemed to be withdrawn, date of legal effect [2014/08]
	02.10.2013	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2014/08]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 02.07.2010
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	26.04.2011	Request for further processing filed
	26.04.2011	Full payment received (date of receipt of payment) Request granted
	16.05.2011	Decision despatched
Fees paid	Renewal fee
	16.06.2005	Renewal fee patent year 03
	12.10.2006	Renewal fee patent year 04
	12.10.2007	Renewal fee patent year 05
	31.03.2008	Renewal fee patent year 06
	13.10.2009	Renewal fee patent year 07
	25.10.2010	Renewal fee patent year 08
	25.10.2011	Renewal fee patent year 09
	23.10.2012	Renewal fee patent year 10
	Penalty fee
	Additional fee for renewal fee
	31.10.2013	11 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]WO9609043 (ALEXION PHARMA INC [US]) [Y] 1-15 * page 4, lines 7-30 * * page 8, line 34 - page 9, line 9 * * page 13, lines 19-26 * * page 25, lines 18-19; figures 1-4; examples 1-2 *;
		[Y]US5614370 (KONTEATIS ZENON [US], et al) [Y] 1-15 * column 2, lines 14-25 *;
		[Y] - WOODRUFF TRENT M ET AL, "Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat", ARTHRITIS AND RHEUMATISM SEP 2002,, (20020901), vol. 46, no. 9, pages 2476 - 2485, XP002564520 [Y] 1-15 * page 2483, column 2, paragraphs 2-3; figures 6-8 * * page 2483, line bridging pg 2484 * DOI: http://dx.doi.org/10.1002/art.10449
		[A] - ONUMA HIROYUKI ET AL, "Expression of the anaphylatoxin receptor C5aR (CD88) by human articular chondrocytes", RHEUMATOLOGY INTERNATIONAL, (200206), vol. 22, no. 2, ISSN 0172-8172, pages 52 - 55, XP002569141 [A] 1-15 * abstract * * page 54, column 2, line last * * page 55, column 1, paragraph 2 * DOI: http://dx.doi.org/10.1007/s00296-002-0199-6
		[A] - POBANZ J M ET AL, "C5A MODULATION OF INTERLEUKIN-1BETA-INDUCED INTERLEUKIN-6 PRODUCTION BY HUMAN OSTEOBLAST-LIKE CELLS", JOURNAL OF PERIODONTAL RESEARCH, BLACKWELL MUNKSGAARD, COPENHAGEN, (20000601), vol. 35, no. 3, ISSN 0022-3484, pages 137 - 145, XP008052227 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1034/j.1600-0765.2000.035003137.x
	International search	[Y]WO9854180 (ASTRA PHARMA PROD [GB], et al);
		[Y]WO9900406 (UNIV QUEENSLAND [AU], et al);
		[Y]WO9902501 (ASTRA PHARMA PROD [GB], et al)
	Examination	- SCHWARTZMAN SERGIO ET AL, "Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?", ARTHRITIS RESEARCH & THERAPY 2004 LNKD- PUBMED:15228615, (2004), vol. 6 Suppl 2, ISSN 1478-6362, pages S3 - S11
		- UCHIDA TAKAFUMI ET AL, "Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid.", JOURNAL OF PROTEOME RESEARCH 2002 NOV-DEC LNKD- PUBMED:12645617, (200211), vol. 1, no. 6, ISSN 1535-3893, pages 495 - 499
		- NEUMANN ELENA ET AL, "Local production of complement proteins in rheumatoid arthritis synovium.", ARTHRITIS AND RHEUMATISM APR 2002 LNKD- PUBMED:11953970, (200204), vol. 46, no. 4, ISSN 0004-3591, pages 934 - 945
		- VAN DEN BERG W B, "Impact of NSAID and steroids on cartilage destruction in murine antigen induced arthritis.", THE JOURNAL OF RHEUMATOLOGY. SUPPLEMENT FEB 1991 LNKD- PUBMED:2027110, (199102), vol. 27, ISSN 0380-0903, pages 122 - 123
		- weatherall, ledingham, warrell, oxford textbook of medicine, third edition, oxford, new york, tokyo, oxford university press, (1996), vol. 3, pages 2953 - 2983
		- MORELAND L W ET AL, "Management of rheumatoid arthritis: the historical context.", THE JOURNAL OF RHEUMATOLOGY JUN 2001 LNKD- PUBMED:11409142, (200106), vol. 28, no. 6, ISSN 0315-162X, pages 1431 - 1452
		- LANGENEGGER T ET AL, "Drug treatment for rheumatoid arthritis.", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH SEP 1999 LNKD- PUBMED:10627714, (199909), no. 366, ISSN 0009-921X, pages 22 - 30
	by applicant	US5935796
		- A.R. GENNARO, Remington: The Science and Practice of Pharmacy(20 th edition), WILLIAMS & WILKINS, (2000), vol. II
		- LANGER, SCIENCE, (1990), vol. 249, page 1527
		WO2003AU00490
		AU20030902743
		WO2003AU01427

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p